Evercyte brings new human cell line development solutions to 3Rs Days


Evercyte brings new human cell line development solutions to 3Rs Days


Evercyte Logo 150

Press Release | Evercyte GmbH

FEBRUARY 18, 2019

Vienna, Austria: – Innovative biotech manufacturer Evercyte will be an active presence at the RepRefRed Society’s ‘3Rs Days’ at University of Graz, focusing on replacement, refinement and reduction of animal testing.

Evercyte Chief Technology Officer Dr. Regina Grillari, an internationally recognized expert in cell biology and cell line development, will deliver a presentation: “Human cell cultures for establishing relevant and standardizable in vitro test systems”. This will show how the use of human telomerized cell lines as alternative test systems can provide superior alternatives to live animal models. Dr. Grillari’s presentation will be during the afternoon session of Day Two of the meeting on February 28.

Cell line products

Evercyte will also be an exhibitor at the event with the Evercyte Booth showcasing its cell lines and services focused on the development of customer-tailored human cell lines, cell based assays and gene editing studies.

“We welcome this meeting as an ideal opportunity to show the audiences of academics and scientists in medical research universities and commercial institutions that human telomerized cells present the most robust and reproducible system for cell based assays and in vitro toxicology due to unlimited cell supply,” commented Regina Grillari.

“I will explain how the primary key functionalities and genetic stability upon life span extension of the cells are maintained and not changed in human telomerized cells and that they can therefore provide a value-added alternative to animal testing and cancer cell models,” Dr. Grillari added.

About Evercyte

Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.

Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.

Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.

About 3Rs Days 2019

The association Verein zur Förderung von alternativen Biomodellen (RepRefRed Society) was founded in 2016 to facilitate alternative means to animal experiments, focused on the international aspiration to replace, refine and reduce animal testing.

The Society promotes its ‘3Rs Days’ annual meeting as a platform for knowledge transfer between scientists committed to enhancing animal experiment protocols and enforce the reduction and refinement of these experiments.

The 2019 3Rs meeting is a two-day event opening February 27 at the BioMed Research Department of Medical University of Graz in Austria.

The meeting is organised by the RepRefRed Society with further information at: http://www.reprefred.eu/en/about-us/news/view/news/detail/News/zweiter-3rs-tag-2019-17.html

Media Contacts

Irene Redlinghofer, Business Development and Project Management, Evercyte GmbH
Tel: +43 699 107 09 401
Email: office@evercyte.com

Resources

Click on Evercyte at 3Rs Day for other information.
Click on Evercyte to contact the company directly.
Click on Evercyte product catalogue for detailed offers .

Dr. Regina Grillari, Chief Technology Officer, Evercyte GmbH

Dr. Regina Grillari, Chief Technology Officer, Evercyte GmbH


Supplier Information
Supplier: Evercyte GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 699 10 709 401
Website: http://www.evercyte.com


Comments are closed.